This amount is in addition to the nearly $12 million in series B financing the company recently raised. It plans to use the funds for two clinical trials to further prove the efficacy of Mi-eye, Trice Medical’s proprietary visualization device. The FDA-cleared device aims to help physicians perform diagnostic arthroscopies, according to the report.
More articles on devices:
5 things to know about the SpineGuard “smart screw” European patent
Medtronic Spinal employees rack-up 4.8k charitable hours — 5 things to know
X-Bolt Orthopaedics receives U.S. patent for jig device in hip nailing system
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
